Keywords
How to Cite
Abstract
Abstract. In Russia, prostate cancer is one of the most common cancers in men. Radical prostatectomy is an established option to treat localized prostate cancer. Almost 35% of patients will face prostate cancer progression within 10 years following radical prostatectomy.
Purpose. To assess the ability of PSA density to predict biochemical relapse and detect unfavorable pathological features among patients suffering from localized prostate cancer treated with radical prostatectomy.
Material and methods. The study evaluated 147 patients with localized prostate cancer who underwent an open or laparoscopic retropubic radical prostatectomy between February 2001 and August 2015. The assessment of prognostic and clinical significance of PSA density took place.
Results. Biochemical recurrence was observed in 53 (36.01%) patients. PSA density (p = 0.006), Gleason score (p = 0.0006), pathological stage T (p = 0.002), extraprostatic extension (p = 0.019), seminal vesicle invasion (p = 0.001) and prostate cancer upstaging (p=0.0007) were found to significantly correlate with biochemical relapse risk. We established a relationship between PSA density and unfavorable pathological features detection following radical prostatectomy. Using ROC – curve analysis (AUC=0,635, р=0,005) we determined PSA density threshold of (>0,309 ng/mL/cc) – when exceeded, was associated with statistically significant decrease in disease – free survival. According to the results of multivariate analysis – PSA density, abnormal Gleason score and seminal vesicle invasion has proven to influence disease – free survival (p < 0.05).
Conclusion. We have clearly demonstrated a PSA density as an important prognostic tool of high clinical relevance, which may aid in biochemical relapse risk estimation. A PSA density parameter incorporation into preoperative nomograms may increase the predictive potential of latter.
References
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). 2019:250–250 [Kaprin A, Starinsky V, Petrova G et al. Population-based registry of cancer patients in the Russian Federation. 2019:250–250 (In Russ.)].
Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients // J Urol. 2002;167(2 Pt 1):528–534. doi:10.1097/00005392-200202000-00018
Blute ML, Bergstralh EJ, Iocca A et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy // J Urol. 2001;165(1):119–125. doi:10.1097/00005392-200101000-00030
Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer // J Urol. 2003;169(2):517–523. doi:10.1097/01.ju.0000045749.90353.c7
Mottrie A, De Naeyer G, Novara G et al. Robotic radical prostatectomy: a critical analysis of the impact on cancer control // Curr Opin Urol. 2011;21(3):179–184. doi:10.1097/MOU.0b013e328344e53e
Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy // JAMA. 1999;281(17):1591–1597. doi:10.1001/jama.281.17.1591
Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 // Urology. 2007;69(6):1095–1101. doi:10.1016/j.urology.2007.03.042
Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer // J Urol. 1992;147(3 Pt 2):815–816. doi:10.1016/s0022-5347(17)37393-7
Radwan MH, Yan Y, Luly JR et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure // Urology. 2007;69(6):1121–1127. doi:10.1016/j.urology.2007.01.087
Sfoungaristos S, Perimenis P. PSA density versus risk stratification for lymphadenectomy-making decision in patients with prostate cancer undergoing radical prostatectomy // Int Urol Nephrol. 2011;43(4):1073–1079. doi:10.1007/s11255-011-9942-9
Freedland SJ, Wieder JA, Jack GS et al. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score // J Urol. 2002;168(1):110–115.
Freedland SJ, Kane CJ, Presti JCJr et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base // J Urol. 2003;169(3):969–973. doi:10.1097/01.ju.0000051400.85694.bb
Jones TD, Koch MO, Bunde PJ et al. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy? // BJU Int. 2006;97(3):480–484. doi:10.1111/j.1464-410X.2006.06022.x
Kundu SD, Roehl KA, Yu X et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness // J Urol. 2007;177(2):505–509. doi:10.1016/j.juro.2006.09.039
Brassell SA, Kao TC, Sun L et al. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer // Urology. 2005;66(6):1229–1233. doi:10.1016/j.urology.2005.06.106
Magheli A, Rais-Bahrami S, Trock BJ et al. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy // J Urol. 2008;179(5):1780–1784. doi:10.1016/j.juro.2008.01.032
Богомолов О.А., Школьник М.И., Жаринов Г.М. Предоперационная
кинетика простатспецифического антигена как фактор прогноза
безрецидивной выживаемости после радикальной простатэктомии. //
Онкоурология. 2014;10(4):47-51. https: // doi: 10.17650/1726-9776-2014-
-4-47-51 (Bogomolov OA, Shkolnik MI, Zharinov G.M. The preoperative
kinetics of prostate-specific antigen as a predict of relapse-free survival
after radical prostatectomy. // Cancer Urology. 2014;10(4):47-51. (In Russ.)
https: // doi: 10.17650/1726-9776-2014-10-4-47-51)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021